Roper Strikes $1.65 Billion Deal to Buy Autism Therapy Software Provider CentralReach

MT Newswires
24 Mar
Roper ROP.jpg -Shutterstock
Roper Technologies (ROP) said Monday that it agreed to acquire CentralReach, an autism therapy software provider, in a $1.65 billion deal that it expects to close within the next two months.

Roper is buying CentralReach from software investor firm Insight Partners, subject to regulatory approval. The $1.65 billion price tag includes a $200 million tax benefit.

"CentralReach is a fantastic business with clear niche market leadership, mission critical and high (return on investment) solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion," Roper Chief Executive Neil Hunn said.

Software and technology company Roper expects about $175 million in revenue contribution and $75 million in earnings before interest, taxes, depreciation, and amortization from CetralReach over a 12-month period ending June 30, 2026. It said CentralReach is anticipated to deliver "sustainable" organic revenue and EBITDA growth of more than 20%.

At the end of January, Roper forecast annual revenue growth of more than 10% for 2025.

In a separate statement, CentralReach said it will continue to operate independently under its current leadership. Its software and services help organizations that serve individuals with autism and intellectual and developmental disabilities.

"With Roper's long-term investment and commitment, CentralReach now has a permanent home where we can continue to scale, innovate, expand our impact, and continue to advance our mission in an even faster and more significant way than we have to date," CentralReach CEO Chris Sullens said.

Insight Partners made a significant investment in CentralReach in 2018. "We are excited to see the company continue its growth and expanding its impact, now with the added strength of Roper," Insight Partners Managing Director Richard Wells said.













Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10